Consistent with a common pathogenic background, IDH1 and IDH2 mutation-positive AML cases share several clinical features, including older age at onset, higher platelet counts, and an association with intermediate cytogenetic risk [11, 14, 18–28]. Here, IDH2 is linked to acute myeloid leukemia.